WO1998052644A1 - System zur photodynamischen behandlung von lebewesen, deren organen und/oder geweben - Google Patents
System zur photodynamischen behandlung von lebewesen, deren organen und/oder geweben Download PDFInfo
- Publication number
- WO1998052644A1 WO1998052644A1 PCT/EP1998/002933 EP9802933W WO9852644A1 WO 1998052644 A1 WO1998052644 A1 WO 1998052644A1 EP 9802933 W EP9802933 W EP 9802933W WO 9852644 A1 WO9852644 A1 WO 9852644A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- data
- sensor
- tissue
- light source
- light
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 16
- 238000002428 photodynamic therapy Methods 0.000 title claims abstract description 12
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 26
- 230000003595 spectral effect Effects 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- -1 Na + Chemical class 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 3
- 235000017168 chlorine Nutrition 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 claims description 3
- 230000000258 photobiological effect Effects 0.000 claims description 3
- 229940109328 photofrin Drugs 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical class [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- PBHVCRIXMXQXPD-UHFFFAOYSA-N chembl2369102 Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1C=C2 PBHVCRIXMXQXPD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical class Cl* 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 235000009421 Myristica fragrans Nutrition 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000001115 mace Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 229940015493 dihematoporphyrin ether Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003569 hematoporphyrin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ATNMPCPGYQSWBN-REOHCLBHSA-N (3s)-3-amino-4-chloro-4-oxobutanoic acid Chemical compound ClC(=O)[C@@H](N)CC(O)=O ATNMPCPGYQSWBN-REOHCLBHSA-N 0.000 description 1
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 description 1
- RKEBXTALJSALNU-LDCXZXNSSA-N 3-[(3R,21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-3-methoxycarbonyl-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C([C@@H](C(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)O)C4=N3)C(=O)OC)O)C)C RKEBXTALJSALNU-LDCXZXNSSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000003348 petrochemical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- OSQUFVVXNRMSHL-LTHRDKTGSA-M sodium;3-[(2z)-2-[(e)-4-(1,3-dibutyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)but-2-enylidene]-1,3-benzoxazol-3-yl]propane-1-sulfonate Chemical compound [Na+].O=C1N(CCCC)C(=S)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 OSQUFVVXNRMSHL-LTHRDKTGSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00057—Light
Definitions
- the invention relates to a system for the photodynamic treatment of living beings, their organs and / or tissues, comprising a device in which a light source which can be controlled by means of a computer which is advantageously connected to a self-adapting database is provided, and at least one Photosensitizer.
- the photodynamic treatment of living organisms, their organs and / or tissues is based on the fact that special photosensitizers trigger biophotochemical effects in the body.
- photosensitizers are used, which after administration to the patient preferentially accumulate in the tumor tissue with a significantly higher concentration, based on the normal tissue.
- the photosensitizer thus becomes the marker of the proliferating cells, the fluoromethical detection being used for radiation diagnosis by irradiation, and the photosensitizers by photochemically toxic conversion in the selective therapy of proliferating cells, i. H. can be used in the fight against cancer.
- the treatment is carried out in that a photosensitizer is added to the body and after a waiting period of up to 3 days, light is emitted into the tissue to be treated with the aid of a light source for an empirically determined time without optimal regulation.
- the object of the present invention was therefore to provide a system which does not have the disadvantages mentioned.
- A a device in which a light source which can be controlled with respect to the intensity, the time and / or the spectral bands with the aid of a computer provided with at least one so-called expert database and possibly at least one sensor for determining the reaction of the treated animal, its tissue and / or Organs is provided, the sensor being connected to the same computer which determines the individual data of the healthy tissue determined by the sensor as so-called individual target values with the help of the expert database and / or the individual data of the treated tissue ascertained by the sensor as so-called therapy data with the aid of a So-called work database is analyzed and compared with a comparator with the individual target values and / or data from the expert database and controls the light source according to the result of the comparison, and
- the light source and thus the light with respect to the intensity and / or spectral bands and / or time is determined by means of a computer with the aid of the databases mentioned in order to achieve a predetermined spectral pattern (photon energy pattern), preferably one Sequence of patterns, controlled.
- a predetermined spectral pattern photon energy pattern
- Spectral patterns are to be understood as a time-variable and / or spectrally structured light which consists of one or more spectral bands.
- the simplest spectral pattern can be characterized using a four-dimensional vector in which the vector coordinates are the energy of the band, the bandwidth, the mean band wavelength and the time. These four vectors are specified via a corresponding computer of the light source, the computer being preset according to the individual data.
- the computer is provided with an expert database.
- key data for therapeutic treatment are already available on the computer, so that for the treatment of a certain type of proliferative cells, i. H. a certain type of tumor or cancer, clinically proven spectral patterns can already be used, which means that there is no need for lengthy experimentation.
- the computer will preferably be connected to sensors for recording data of the tissue to be treated.
- the computer can be provided with a comparator for comparing the data recorded by the sensor or sensors with that of the expert database, as a result of which it can be determined immediately whether the tissue responds to the spectral pattern in the desired manner.
- the sensors can also preferably be connected to a so-called work database, which processes the determined data of the tissue to be treated as individual therapy data for the comparator in order to compare this data with the data from the expert database.
- a so-called work database which processes the determined data of the tissue to be treated as individual therapy data for the comparator in order to compare this data with the data from the expert database.
- these can also be designed to record data of the healthy tissue, which are preferably passed on to the expert database as individual target values at the beginning of the therapy and, if necessary, are used to determine the control conditions of the light source with the aid of the expert database, wherein the comparator compares the acquired target values of the healthy tissue with the actual values (therapy values) of the proliferating cells during the therapy and the light source is controlled accordingly.
- a beam coupler for the targeted introduction of the light rays into the tissue can be connected upstream of the light source, whereby an optimal utilization of the light radiation is achieved.
- the beam coupler can have a lens and / or light guide and / or mirror system for aligning and / or selecting the light beams.
- a reflection prism or cone can be switched on for aligning and / or focusing the light rays in the beam path.
- a light guide system for aligning and / or selecting the light beams can be provided. All of this serves the purpose of specifically developing the photon energy pattern already mentioned above.
- the devices provided in the beam coupler for aligning and / or selecting the light beams for the geometric design of the surface to be irradiated can be mutually adjustable, which has the purpose that the radiation is aimed exclusively at the diseased tissue and healthy tissue is not detected by the radiation .
- sensor couplers can be connected upstream of the sensors to selectively record the data of the tissue to be treated.
- the sensor couplers can be constructed analogously to the beam couplers in order to analyze the photon patterns in this way and to pass them on to the computer in a correspondingly prepared manner.
- the sensor coupler can also have electrodes and / or measuring probes for the additional determination of physical, electrophysiological and / or physiological-chemical measurement data.
- the concentration of oxygen, preferably of different oxygen states, of metabolic compounds such as glucose, phosphates, amino acids, proteins, lactic acid, enzymes, radicals, amines, of ions such as Na + , Ka + , Ca 2+ , of C0 can be used as therapy-relevant data 2
- the concentration of various oxygen states, the temperature, the concentration of glucose and / or lactic acid are preferably recorded as data.
- the light source can be designed as a broadband light source, which is followed by a light distributor and one or more spectral band filters and / or intensity modules.
- a simple light source can thus be used, and the device is also ready for a wide variety of applications, since adaptation is possible simply by changing the light distributor and / or the spectral band filter and / or intensity modules.
- each component can be separately controllable in order to be able to generate a finer spectral pattern in this way.
- the light source can also be designed as an intensity-controllable laser, where appropriate a plurality of lasers can be provided, as a result of which then Light distributors and spectral band filters can be dispensed with.
- a broadband light source with a downstream spectral band filter and / or intensity modules can also be combined with an intensity-controlled laser, which enables combined treatment of tissues if this is classified as cheap, with the additional result that the device is highly universal.
- the spectral band filters and / or intensity modules or the intensity-controlled laser can be followed by a light integrator, with the light integrator being common to all units in the case of combined designs.
- the output of the light integrator can be connected directly to the input of the beam coupler.
- the sensors are preferably designed for the separate acquisition of the spectral pattern and / or electrophysiological and / or physiological-chemical data, preferably photobiological and / or metabolistic data, which ensures that each signal is acquired separately and can also be processed in this form.
- the sensor for determining the spectral pattern can have monochromators and / or, optionally controllable, filters and / or spectral analyzers, which enables an accurate analysis of the spectral patterns reported by the tissue.
- each of the sensors can be followed by a data converter which is matched to the data to be determined and which then transmits these data to the work database in a correspondingly processed manner.
- the system according to the invention comprises at least one photosensitizer which can be supplied to the life being to be treated, its organ (s) and / or tissues in all common forms. Administration is preferably by injection or infusion. In general, between 0.15-5 mg photosensitizer / kg body weight, depending on the organ to be treated, the size of the proliferating cell tissue, ie the proliferation such as a tumor, cancer, are dosed and generally after the administration of 0.5-96 hours Enrichment in the tissue to be treated waited with the photodynamic treatment.
- porphyrins such as. B. HpD (hematoporphyrin derivative), HDE (dihematoporphyrin ether), Photofrin®, which is a mixture of essentially dimeric and oligomeric dihematoporphyrin ether, of which the trimeric ether according to formula I and according to formula ⁇ is one of the essential compounds of Photofrin®, namely the Na Connection of hematoporphyrin ether (ester).
- HpD hematoporphyrin derivative
- HDE dihematoporphyrin ether
- Photofrin® which is a mixture of essentially dimeric and oligomeric dihematoporphyrin ether, of which the trimeric ether according to formula I and according to formula ⁇ is one of the essential compounds of Photofrin®, namely the Na Connection of hematoporphyrin ether (ester).
- chlorines such as 5, 10, 15, 20-tetra (m-hydroxyphenyl) chlorine (Foscan®) or mTHPC according to the formula m, MACE (monoaspartylchlorine) or Npe6 (a product of Nippon Petrochemicals Ltd, Japan)
- pheophorbides such as pheophorbide a of formula V.
- Preferred photosensitizers are also benzoporphyrin derivatives (BPD), as represented in formula VI,
- Rl R 2 and means -C ⁇ 2Me
- R 3 (CH 2 ) 2C0 2 Me or (CH2) 2CO 2 H
- BPDMA and BPDMB can be named as representatives.
- phthalocyanines such as. B. the zinc phthalocyanine (ZnPc) or the disulfonated aluminum phthalocyanine of the formula vTJI
- Porphins like TPPS4 Mesotetrasulfonatophenylporphin
- Porphycene like ATMPn Purpurins like SnET2 (Tinethyletiopurpurin) Texaphyrins like Lu-Tex (Lutetium Texaphyrin)
- endogenous photosensitizers in situ in the living being, its organs and / or tissues, in which compounds, such as ⁇ -aminolevulinic acid, are supplied in the usual form and administration, which stimulate the formation of endogenous photosensitizers.
- the photosensitizers mentioned can be used individually or in a mixture.
- the wave ranges for the excitation of the photosensitizers in the course of photodynamic therapy are largely known, as is their production.
- proliferating cells of all kinds including vessels and / or tumors, cancerous ulcers, coronary stenoses
- the targeted use of photosensitizers and the described device which works with a controlled and adapted light pattern, means that it is significantly higher To achieve effectiveness over the known systems and to selectively destroy the proliferating cells.
- Fig. 1 shows a conventional treatment device.
- FIG. 2 shows a modified treatment device in which the light source can be controlled via experimentally determined data.
- FIG. 3 schematically illustrates a first embodiment of a beam coupler with a broadband light source.
- Fig. 4 shows a modified design of the beam coupler for a broadband light source.
- FIG. 5 shows a beam coupler with optical fibers, a separate fiber being provided for each spectrum.
- FIG. 6 shows a configuration similar to FIG. 5, with only one fiber strand starting from the light source, which then splits depending on the number of spectral bands.
- FIG. 7 shows the construction of the controllable light source, which has a broad-spectrum band-emitting light source.
- FIG. 8 shows a configuration similar to FIG. 7, but for intensity-controllable lasers.
- FIG. 9 shows a combined design which has a broad-spectrum band-emitting light source and a plurality of intensity-controllable lasers.
- 10 shows an overall compilation of the device used according to the invention, which in addition to the radiation part also has a sensor part for determining tissue data.
- FIG. 11 illustrates the structure of a sensor coupler and the connection to the tissue.
- FIG 14 illustrates an overall design of the device with intensity-controllable lasers, the control being carried out by means of an expert database without feedback from the tissue.
- FIG. 15 shows an embodiment analogous to FIG. 14, which additionally has sensor couplers and sensors for determining tissue data changed by the irradiation.
- the tissue 1 of the patient is irradiated with a light source 2, which is acted upon by a power supply 3.
- This light source 2 can be switched via an on and off device 4.
- the light source is placed at a distance from the patient's tissue, so that a rather unspecific radiation hits the tissue, whereby considerable radiation losses to the surroundings cannot be ruled out.
- FIG. 2 shows the device used according to the invention, in which the tissue 10 to be treated and / or healthy is connected via a beam coupler 11 to a light source 12, the intensity and / or spectral pattern of which can be controlled.
- Pattern control electronics 13 are provided for this control and are controlled by a computer 14. Both the light source 12 and the pattern control electronics 13 and the computer 14 are supplied by a current source 15. Is inside the calculator an expert database 16 is provided, in which empirically determined data for the treatment of the tissue to be irradiated are stored.
- the beam coupler 11 is brought up to the tissue to be treated in such a way that the field irradiated by the beam coupler corresponds to the tissue to be treated.
- the beam coupler receives the light beams or the spectral pattern via the beam output 17 of the light source 12, which is connected to the pattern control electronics 13 via the lines 18.1 to 18.n.
- the number of lines 18 depends on the number of bands or spectral ranges with which the light source is exposed.
- the pattern control electronics 13 receives the corresponding control commands via the control signal output 19 from the computer 14, which takes the corresponding data from the expert database.
- FIGS. 3-6 schematically show different variants of the beam coupler 11, FIG. 3 showing a beam coupler made up of lenses 20 and deflecting mirrors 21.
- the pattern output by the beam coupler 11 can be changed by appropriate selection or arrangement of the lenses and corresponding pivoting of the mirrors 21.
- the beam output 17 acts on a beam coupler 11, in which the light rays strike a refractive cone or a refractive prism 22, the reflected light rays being directed onto the tissue 10 via deflecting mirrors 21.
- the beam coupler is designed as an optical fiber bundle, with a predetermined number of optical fibers 23, etc. the fibers 23.1 to 23. n is made. Each of these fibers transmits a specific spectral range, so that the commonality of the light fibers then emits a predetermined spectral pattern to the tissue 10. 6 that a single fiber bundle 24 leads away from the beam exit 17, which is divided along the way into a fiber bundle 24.1 to 24.n, a specific spectral pattern also being achievable through this division.
- 7 shows the structure of the intensity and / or spectrally controllable light sources 12, which is acted upon by the pattern control electronics via the lines 18.1 to 18.n.
- This light source has a broad spectral band emitting light source 25, which is connected to a light distributor and / or diaphragm 26.
- the light emanating from the light distributor and / or diaphragm 26 is forwarded via a line 27 to the spectral band filter 28.1 to 28.n and broken down there into a corresponding spectral band pattern.
- This spectral band pattern is then fed via lines 29 to intensity modulators 30.1 to 30. n, which then feed the intensity-modulated light beams via line 31 to a light integrator 32.
- the light entering the light integrator is fed to the beam coupler via the beam output 17 and is then emitted from it to the tissue 10.
- the spectral band filters 28.1 to 28.n can be controlled via a spectral filter 33 which is acted upon by the pattern control electronics 13 via the lines 18.x to 18.y.
- the intensity modulators 30.1 to 30.n can be controlled via corresponding modulator control electronics 34, which are also supplied with data by the pattern control electronics 13 via a line 18.n.
- this pattern control electronics 13 is supplied with data from the expert database 16 by the computer 14 via a signal output 19.
- At least one intensity-controllable laser 35.1 is provided as the light source instead of a broad-spectrum band-emitting light source, and - as can be seen from FIG. 8 - there may be an indefinite number up to 35.n.
- These intensity-controllable lasers are connected via lines 36.1 to 36.n to intensity control devices, via which the lasers can be acted upon accordingly.
- the light emerging from the intensity-controllable lasers, which already have a special spectral band due to the laser formation, is fed again via line 31 'to the light integrator 32, which then acts on the beam coupler 11 again via the beam output 17. Due to the individual controllability of the intensity-controllable lasers 35.1 to 35.
- each of the spectral bands can be controlled separately with regard to the intensity and / or time. 7, where the intensity modulators then have to be controlled via special modulator control electronics 34, the spectral filter control 33 also having to be acted upon accordingly, and so on. in cooperation with the modulator control electronics 34.
- FIG. 9 The embodiment variant shown in FIG. 9 is a combination of the embodiments of FIGS. 7 and 8, the same reference numerals as in FIGS. 7 and 8 being used. This gives the possibility of achieving even more precise regulation of the irradiation, since the laser beams can be associated with the rays coming from the broad-spectrum band as a supplement, so that very narrow spectral ranges can be amplified in order to achieve the desired irradiation.
- the variant according to FIG. 10, as a preferred embodiment, has the embodiment already described for FIG. 2 as the irradiation part, but a data acquisition part is additionally provided, which consists of a sensor coupler 37, a sensor 38, a sensor data input 39 and a sensor controller 40 .
- the sensor coupler 37 is connected to the sensors 38 via corresponding lines 41, a corresponding sensor control channel 42 and a sensor data channel 42 ′ leading to the sensor control.
- a work database 43, a comparator 44 and an adaptive control system 45 are also provided in the computer 14.
- the direction of the reaction is determined via the adaptive control system and, depending on the determined value and trend, the sensor control 40 and the pattern control electronics are then acted upon accordingly, so that the pattern control electronics 13 then adjusts the intensity and / or spectrally controllable light source 12 in such a way that the desired reaction direction is achieved.
- the sensor is also doped appropriately via the sensor controller 40 in order to have the sensor ready for receiving the changed data.
- the sensor coupler 37 can be constructed similarly to the beam coupler 11, it being possible for a lens system and / or a light guide system and / or mirror system or a combination of these systems to be present within this sensor coupler. These configurations correspond approximately to the structure shown in FIGS. 3 to 6. This lens system and / or light guide system and / or mirror system is denoted by 45 in FIG. 11.
- electrodes 46 and other measuring probes 47 can also be present, by means of which electropotentials, oxygen concentrations or other physical and / or physiological-chemical measurement data, as stated above, can be obtained.
- the electrodes 46 can be surface and / or probe electrodes or microelectrodes which can derive and detect potential differences present in the tissue.
- the other measuring probes can be used continuously or discontinuously to record the concentration or its changes in a wide variety of substances, as already listed.
- measuring probes can be used to record geometric positions, volumes, masses and vibrations. Tissue impedance, NADH, MPA, blood flow and / or circulation can also be measured. All of these data can be used for tumor diagnosis and subsequently for information about the success of photodynamic therapy. In particular, the Combination of the measurement of oxygen, temperature, glucose and / or lactic acid has proven to be particularly favorable.
- the evaluation in sensor 38 is then shown in FIG. 12, the measurements of the spectral analysis in spectral sensor 48, the chemical-physiological and electro-physiological data in sensor 49 and the other sensor data in sensor 50 being recorded via line 41.
- Each of these sensors is preceded by a special controller 51, 52 and 53, which are acted on by lines 54, 55, 56 from the sensor data controller 57, which are acted on by the sensor controller 42.
- the sensor data are derived from the data output of the spectral control 51, the parameter control 52 or 53 and are also added to the sensor data control 57, which then feeds the sensor data via line 43 to the sensor data input 39 of the computer 14.
- monochromators and / or filters or controllable filters and / or spectral analyzers 58 are provided, which are acted upon by the spectral sensor controller 51, which in turn receives the commands from the sensor controller 40 via the line 42 .
- the data determined by the monochromators and / or filters and / or controllable filters or spectral analyzers 58 are fed to the sensor data controller 57 via a photoelectric converter 59 and the corresponding data output 54.
- the 10 can also be controlled so that the data supplied via the sensor coupler 37, the sensors 38, the sensor data channel 42 'and the computer 14 are those which are read from a healthy tissue part. These data are then entered into the expert database 16 as so-called target values and the tissue is irradiated via the light source 12 and the beam coupler 10, the reaction of the tissue being determined again via sensors.
- the setpoint data of the expert database ascertained about the healthy tissue are then compared with the data ascertained by the sensors of the diseased tissue after the irradiation in the comparator 44 and via the Working database evaluated, in which case the adaptive control system 45 again evaluates the direction of the reaction.
- FIG. 14 shows an irradiation device analogous to FIG. 2, etc. a device equipped with intensity-controllable lasers 35.1 to 35.n, the lasers being acted upon by lines 14.1 to 36.n from the computer 14 via a D / A converter and an address and data separator.
- a holder for the beam coupler for attachment to the tissue 10 is designated.
- the input and monitoring unit is generally indicated at 61.
- the device shown in FIG. 15 corresponds to the device shown in FIG. 10, the irradiation device again being formed by lasers that can be controlled by intensity and / or wavelength.
- the sensor 38 has a controllable spectrophotometer and a pH probe, each of which has a D / A converter and is connected to the computer via an address and data selector.
- the irradiation part of the system corresponds to that of FIG. 14.
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-7010878A KR100536882B1 (ko) | 1997-05-23 | 1998-05-19 | 생체, 이들의 기관 및/또는 조직의 광동역학적 처리를위한 시스템 |
AU79136/98A AU7913698A (en) | 1997-05-23 | 1998-05-19 | System for photodynamic therapy of living organisms and their organs and/or tissues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19721489.4 | 1997-05-23 | ||
DE19721489A DE19721489A1 (de) | 1997-05-23 | 1997-05-23 | System zur photodynamischen Behandlung von Lebewesen, deren Organen und/oder Geweben |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998052644A1 true WO1998052644A1 (de) | 1998-11-26 |
Family
ID=7830220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/002933 WO1998052644A1 (de) | 1997-05-23 | 1998-05-19 | System zur photodynamischen behandlung von lebewesen, deren organen und/oder geweben |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR100536882B1 (de) |
CN (1) | CN1198667C (de) |
AU (1) | AU7913698A (de) |
DE (1) | DE19721489A1 (de) |
WO (1) | WO1998052644A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008062000A1 (en) * | 2006-11-20 | 2008-05-29 | Spectracure Ab | System and method for predicting and/or adjusting control parameters of interstitial photodynamic light therapy |
WO2012062134A1 (zh) * | 2010-11-11 | 2012-05-18 | 天津滨海华医光电技术有限公司 | 光动力治疗肿瘤系统 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821289B2 (en) * | 2003-03-25 | 2004-11-23 | Ceramoptec Industries, Inc. | Efficacy and safety of photodynamic therapy by multiple application protocols with photosensitizers that show extended tumor retention |
CN101485920B (zh) * | 2009-02-09 | 2013-03-06 | 深圳先进技术研究院 | 激光治疗装置 |
IT1403091B1 (it) * | 2010-12-01 | 2013-10-04 | Touch Life Rehab S R L | Metodo per la gestione di protocolli di terapie laser. |
FR2998480B1 (fr) * | 2012-11-28 | 2016-02-12 | Univ Lorraine | Procede pour controler l'activation d'une substance photosensibilisante dans un tissu biologique, et dispositif mettant en œuvre le procede |
KR102439281B1 (ko) | 2018-05-09 | 2022-08-31 | 내셔널 인스티튜츠 포 퀀텀 사이언스 앤드 테크놀로지 | 조직 식별 장치, 조직 식별 시스템, 조직 식별 방법, 조직 식별 프로그램 및 기록 매체 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018646A1 (en) * | 1990-05-30 | 1991-12-12 | European Industries Limited | A device and method for laser photothermotherapy |
EP0473861A1 (de) * | 1990-09-03 | 1992-03-11 | Moretti, Francesco Avv. | Verfahren und Gerät zur Verarbeitung der an einem Lebewesen durch elektrische und elektromagnetische Felder erzeugten Information |
WO1993021842A1 (en) * | 1992-04-30 | 1993-11-11 | Quadra Logic Technologies, Inc. | High-power light-emitting diodes for photodynamic therapy |
EP0604931A2 (de) * | 1992-12-28 | 1994-07-06 | Matsushita Electric Industrial Co., Ltd. | Medizinischer Laser und dessen Verwendung in einem Gerät für Diagnose und Therapie |
US5634922A (en) * | 1989-11-20 | 1997-06-03 | Hamamatsu Photonics K.K. | Cancer diagnosis and treatment device having laser beam generator |
WO1997019725A1 (de) * | 1995-11-24 | 1997-06-05 | Tibor Nagypal | Gerät zur photodynamischen behandlung von lebewesen bzw. organen derselben |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4592361A (en) * | 1982-06-28 | 1986-06-03 | The Johns Hopkins University | Electro-optical device and method for monitoring instantaneous singlet oxygen concentration produced during photoradiation using pulsed excitation and time domain signal processing |
DE3908928A1 (de) * | 1989-03-18 | 1990-09-20 | Messerschmitt Boelkow Blohm | Bildgebendes verfahren und vorrichtung zum dosierten bestrahlen von biologischem gewebe mit laserstrahlung in der medizinischen anwendung |
CH676671A5 (de) * | 1989-07-03 | 1991-02-28 | Teclas Tecnologie Laser S A | |
EP0435506A3 (en) * | 1989-12-19 | 1991-08-14 | Pfizer Hospital Products Group, Inc. | Infrared delivery system with aiming component |
JPH0538369A (ja) * | 1991-08-05 | 1993-02-19 | Ishikawajima Harima Heavy Ind Co Ltd | 癌の治療装置 |
KR100230588B1 (ko) * | 1992-11-20 | 1999-12-01 | 팜 윌리암 엔. | 감광제함유 광역학적 요법제 |
US5514127A (en) * | 1993-02-18 | 1996-05-07 | Central Research Laboratories Limited | Apparatus for irradiating an area with a controllable pattern of light |
-
1997
- 1997-05-23 DE DE19721489A patent/DE19721489A1/de not_active Withdrawn
-
1998
- 1998-05-19 AU AU79136/98A patent/AU7913698A/en not_active Abandoned
- 1998-05-19 WO PCT/EP1998/002933 patent/WO1998052644A1/de active IP Right Grant
- 1998-05-19 KR KR10-1999-7010878A patent/KR100536882B1/ko not_active IP Right Cessation
- 1998-05-19 CN CNB988074052A patent/CN1198667C/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5634922A (en) * | 1989-11-20 | 1997-06-03 | Hamamatsu Photonics K.K. | Cancer diagnosis and treatment device having laser beam generator |
WO1991018646A1 (en) * | 1990-05-30 | 1991-12-12 | European Industries Limited | A device and method for laser photothermotherapy |
EP0473861A1 (de) * | 1990-09-03 | 1992-03-11 | Moretti, Francesco Avv. | Verfahren und Gerät zur Verarbeitung der an einem Lebewesen durch elektrische und elektromagnetische Felder erzeugten Information |
WO1993021842A1 (en) * | 1992-04-30 | 1993-11-11 | Quadra Logic Technologies, Inc. | High-power light-emitting diodes for photodynamic therapy |
EP0604931A2 (de) * | 1992-12-28 | 1994-07-06 | Matsushita Electric Industrial Co., Ltd. | Medizinischer Laser und dessen Verwendung in einem Gerät für Diagnose und Therapie |
WO1997019725A1 (de) * | 1995-11-24 | 1997-06-05 | Tibor Nagypal | Gerät zur photodynamischen behandlung von lebewesen bzw. organen derselben |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008062000A1 (en) * | 2006-11-20 | 2008-05-29 | Spectracure Ab | System and method for predicting and/or adjusting control parameters of interstitial photodynamic light therapy |
WO2012062134A1 (zh) * | 2010-11-11 | 2012-05-18 | 天津滨海华医光电技术有限公司 | 光动力治疗肿瘤系统 |
Also Published As
Publication number | Publication date |
---|---|
AU7913698A (en) | 1998-12-11 |
CN1264314A (zh) | 2000-08-23 |
KR100536882B1 (ko) | 2005-12-16 |
KR20010012910A (ko) | 2001-02-26 |
CN1198667C (zh) | 2005-04-27 |
DE19721489A1 (de) | 1998-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT403990B (de) | Gerät zur photodynamischen behandlung von lebewesen bzw. organen derselben | |
US10914803B2 (en) | Optogenetic magnetic resonance imaging | |
DE60207202T2 (de) | Vorrichtung zur photodynamischen stimulation | |
US20140324138A1 (en) | Wirelessly-powered illumination of biological tissue | |
Budinger et al. | Anatomical connections suitable for the direct processing of neuronal information of different modalities via the rodent primary auditory cortex | |
DE69834827T2 (de) | Phototherapeutische systeme | |
Antinucci et al. | A calibrated optogenetic toolbox of stable zebrafish opsin lines | |
Chen et al. | An integrated circuit for simultaneous extracellular electrophysiology recording and optogenetic neural manipulation | |
WO2007079943A1 (de) | Faseroptisches fluoreszenzsensorsystem | |
EP1372518B1 (de) | Laserbehandlungsgerät mit beleuchtungssystem | |
EP0568666A1 (de) | Vorrichtung zur fotodynamischen energiestimulierung | |
DE10202050A1 (de) | Optisches Bildgebungsverfahren und Vorrichtung zur optischen Bildgebung | |
WO2002028273A2 (en) | Multi-spectral fluorescence imaging and spectroscopy device | |
WO1998052644A1 (de) | System zur photodynamischen behandlung von lebewesen, deren organen und/oder geweben | |
Kruse et al. | Optogenetic modulation and multi-electrode analysis of cerebellar networks in vivo | |
Matsumoto et al. | Causal role of neural signals transmitted from the frontal eye field to the superior colliculus in saccade generation | |
DE69936866T2 (de) | Synergismus von photodynamischen und elektropermeationseffekten auf die zellvitalität als ein neues cytotoxisches mittel | |
Zhang et al. | A method for combining multiple-units readout of optogenetic control with natural stimulation-evoked eyeblink conditioning in freely-moving mice | |
CN117224859B (zh) | 包括焦虑状态评估装置和多靶点时序光刺激和成像装置的系统 | |
Paride et al. | A calibrated optogenetic toolbox of stable zebrafish opsin lines | |
Gartside et al. | Motor, somatosensory, and executive cortical areas elicit monosynaptic and polysynaptic neuronal activity in the auditory midbrain | |
AT520538B1 (de) | Vorrichtung zur flächigen Bestrahlung einer Behandlungsstelle | |
US20100292762A1 (en) | Method for controlling photodynamic therapy irradiation and related instrumentation | |
DE102020108957A1 (de) | Vorrichtung, Verfahren und Computerprogramm zur Fluoreszenzmessung | |
Kruse et al. | Optogenetic Modulation and Multi-Electrode Analysis of Cerebellar Networks In |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98807405.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019997010878 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref document number: 1998549942 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997010878 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997010878 Country of ref document: KR |